The following is cross-posted from our Optum Insights—Government Affairs blog The U.S. Food and Drug Administration (FDA) recently established a more rapid path for pharmaceutical companies to add over-the-counter (OTC) naloxone products to the market to increase access to naloxone – a life-saving medication used for the emergency treatment of opioid-related overdose – and help … Read moreFDA creates faster way to access over-the-counter naloxone products to treat opioid overdoses
On January 4, 2019, CMS released an updated Non Group Health Plan (NGHP) User Guide, version number 5.5. Click here to access the updated User Guide. Here is a summary of the updates.
On January 4, 2019, The Centers for Medicare and Medicaid Services (CMS) released an updated Workers Compensation Medicare Set-Aside (WCMSA) Reference Guide, Version 2.9.
This is a cross-post from our Optum Insights blog. The U.S. Food and Drug Administration’s (FDA) recent decision to grant pediatric exclusivity for Lyrica® ― as it may be used as an adjunctive therapy for partial onset seizures in pediatric epilepsy patients ― extends the period of market exclusivity in the U.S. by an additional … Read moreLyrica® generic delayed until summer 2019 and Pfizer to increase drug prices